|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...910111213141516171819...9899» |
- Enrollment change, Trial withdrawal: Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=0, Withdrawn, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
N=20 --> 0 | Active, not recruiting --> Withdrawn
- Cyramza (ramucirumab) / Eli Lilly
Phase classification, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - Jun 10, 2016
P1b, N=9, Active, not recruiting, Sponsor: Eli Lilly and Company
N=20 --> 0 | Active, not recruiting --> Withdrawn Phase classification: P1 --> P1b
- | ND-L02-s0201 / Nitto Denko, BMS
Trial completion, Phase classification: Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) (clinicaltrials.gov) - Jun 10, 2016
P1b/2, N=25, Completed, Sponsor: Nitto Denko Corporation
Phase classification: P1 --> P1b Active, not recruiting --> Completed | Phase classification: P1 --> P1b/2
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jun 5, 2016
P4, N=132, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Phase classification: P1 --> P1b/2 Trial primary completion date: Jun 2017 --> Dec 2017
- || vesatolimod (GS-9620) / Gilead
Trial primary completion date: Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection (clinicaltrials.gov) - Jun 5, 2016
P=N/A, N=500, Enrolling by invitation, Sponsor: Gilead Sciences
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Oct 2019 --> Sep 2021
- Ibrance (palbociclib) / Pfizer
Trial primary completion date: A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib (clinicaltrials.gov) - Jun 5, 2016
P1, N=28, Recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2019 --> Sep 2021 Trial primary completion date: Apr 2017 --> Sep 2016
- Ximency (daclatasvir/asunaprevir/beclabuvir) / BMS, beclabuvir (BMS-791325) / BMS
Enrollment change, Trial withdrawal: HEPCOG-II: Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (clinicaltrials.gov) - Jun 5, 2016
P4, N=0, Withdrawn, Sponsor: Kirby Institute
Trial primary completion date: Apr 2017 --> Sep 2016 N=35 --> 0 | Not yet recruiting --> Withdrawn
- ||| Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion, Trial primary completion date: Hepatitis B Booster Study in Adolescence (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=359, Completed, Sponsor: University of British Columbia
N=35 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2015
- Trial completion: Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=7, Completed, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2015 Recruiting --> Completed
- sirolimus / Generic mfg.
Trial completion: Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jun 1, 2016
P2, N=45, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: PRIGA: Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis (clinicaltrials.gov) - May 27, 2016
P4, N=74, Active, not recruiting, Sponsor: Sara Varea
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || sorafenib / Generic mfg.
Enrollment closed: OPTIMIS: Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib (clinicaltrials.gov) - May 25, 2016
P=N/A, N=1670, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial suspension, Trial primary completion date: Hepatocyte Transplantation for Acute Decompensated Liver Failure (clinicaltrials.gov) - May 21, 2016
P1, N=15, Suspended, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Recruiting --> Suspended | Trial primary completion date: Jan 2016 --> Apr 2017
- Intuvax (ilixadencel) / Mendus
Enrollment change, Trial primary completion date: Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - May 21, 2016
P1, N=18, Recruiting, Sponsor: Immunicum AB
Recruiting --> Suspended | Trial primary completion date: Jan 2016 --> Apr 2017 N=12 --> 18 | Trial primary completion date: Dec 2015 --> Dec 2016
- ||| Biomarker, Trial completion: Biomarkers in Tissue Samples From Young Patients With Liver Cancer (clinicaltrials.gov) - May 19, 2016
P=N/A, N=99, Completed, Sponsor: Children's Oncology Group
N=12 --> 18 | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- Trial primary completion date: The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis (clinicaltrials.gov) - May 19, 2016
P=N/A, N=168, Recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2016
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed
- Enrollment closed: Prognosis Factors of Cardiac Complications After Liver Transplantation (clinicaltrials.gov) - May 19, 2016
P=N/A, N=500, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Januvia (sitagliptin) / Merck (MSD)
Enrollment change, Trial withdrawal: Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI (clinicaltrials.gov) - May 18, 2016
P4, N=0, Withdrawn, Sponsor: University of Missouri-Columbia
Recruiting --> Active, not recruiting N=24 --> 0 | Recruiting --> Withdrawn
- Enrollment open, Trial initiation date: SIMPLIFY: A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use (clinicaltrials.gov) - May 18, 2016
P2, N=100, Recruiting, Sponsor: Kirby Institute
N=24 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Mar 2016
- | Hepacid (pegargiminase) / Polaris Pharma
Enrollment closed, Trial primary completion date: Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - May 18, 2016
P2, N=40, Active, not recruiting, Sponsor: Polaris Group
Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Jul 2016
- |||| voxilaprevir (GS-9857) / Gilead
Trial completion: LEPTON: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (clinicaltrials.gov) - May 14, 2016
P2, N=269, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Jul 2016 Active, not recruiting --> Completed
- Pegasys (pegylated interferon α -2a) / Roche
Trial completion, Trial primary completion date: Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy (clinicaltrials.gov) - May 14, 2016
P=N/A, N=330, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> Jun 2015
- Trial completion: Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - May 14, 2016
P=N/A, N=45, Completed, Sponsor: University of Western Ontario, Canada
Active, not recruiting --> Completed | Trial primary completion date: Mar 2014 --> Jun 2015 Recruiting --> Completed
- || entecavir / Generic mfg.
Enrollment closed, Trial primary completion date: HBVQuant: Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay (clinicaltrials.gov) - May 13, 2016
P=N/A, N=331, Active, not recruiting, Sponsor: Hologic, Inc.
Recruiting --> Completed Completed --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2018
- Trial termination: RAS01: Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases (clinicaltrials.gov) - May 13, 2016
P3, N=300, Terminated, Sponsor: University of Aarhus
Completed --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Sep 2018 Recruiting --> Terminated; Insufficient recruitment
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Enrollment change, Trial termination, Trial primary completion date: Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition (clinicaltrials.gov) - May 13, 2016
P3, N=2, Terminated, Sponsor: Johane Allard
Recruiting --> Terminated; Insufficient recruitment N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Aug 2015; No more eligible patients could be identified.
- ursodeoxycholic acid / Generic mfg.
Enrollment change, Trial withdrawal: CERTO: Ursodeoxycholic Acid And Cholestasis Of Pregnancy (clinicaltrials.gov) - May 13, 2016
P3, N=0, Withdrawn, Sponsor: University of Bologna
N=20 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Aug 2015; No more eligible patients could be identified. N=118 --> 0 | Not yet recruiting --> Withdrawn
- Trial completion, Enrollment change: Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - May 13, 2016
P2, N=20, Completed, Sponsor: Johane Allard
N=118 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | N=40 --> 20
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Enrollment change, Metastases: Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer (clinicaltrials.gov) - May 13, 2016
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=40 --> 20 Active, not recruiting --> Completed | N=51 --> 21
- Biomarker, Trial primary completion date: Development of a Novel Biomarker for Liver Fibrosis (clinicaltrials.gov) - May 13, 2016
P=N/A, N=125, Recruiting, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | N=51 --> 21 Trial primary completion date: Apr 2016 --> Dec 2016
- Trial primary completion date, Metastases: Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors (clinicaltrials.gov) - May 13, 2016
P=N/A, N=10, Recruiting, Sponsor: University of Miami
Trial primary completion date: Apr 2016 --> Dec 2016 Trial primary completion date: Apr 2016 --> Apr 2017
- Trial completion, Enrollment change: Fatty Acids, Genes and Microbiota in Fatty Liver (clinicaltrials.gov) - May 12, 2016
P=N/A, N=205, Completed, Sponsor: Johane Allard
Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Completed | N=165 --> 205
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Trial primary completion date: Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury (clinicaltrials.gov) - May 12, 2016
P=N/A, N=50, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed | N=165 --> 205 Trial primary completion date: Aug 2018 --> Aug 2020
- || Enrollment closed, Enrollment change: Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy (clinicaltrials.gov) - May 12, 2016
P=N/A, N=54, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Aug 2018 --> Aug 2020 Enrolling by invitation --> Active, not recruiting | N=400 --> 54
- Enrollment change, Trial withdrawal, Trial primary completion date, Adherence: Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection (clinicaltrials.gov) - May 11, 2016
P=N/A, N=0, Withdrawn, Sponsor: University of Louisville
Enrolling by invitation --> Active, not recruiting | N=400 --> 54 N=52 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Mar 2016
- Trial primary completion date: Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin (clinicaltrials.gov) - May 10, 2016
P1, N=20, Recruiting, Sponsor: University of North Carolina, Chapel Hill
N=52 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2017 --> Mar 2016 Trial primary completion date: Apr 2016 --> Dec 2016
- Trial primary completion date: VDLS: Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes (clinicaltrials.gov) - May 10, 2016
P3, N=10, Recruiting, Sponsor: University of Massachusetts, Worcester
Trial primary completion date: Apr 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- | metformin / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: METFOVIR: Primary Prevention Hepatocellular Carcinoma by Metformin (clinicaltrials.gov) - May 10, 2016
P3, N=444, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Jun 2015 | Trial primary completion date: Dec 2018 --> Jun 2019
- | Trial completion, Enrollment change, Trial primary completion date: Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection (clinicaltrials.gov) - May 10, 2016
P3, N=135, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Jun 2015 | Trial primary completion date: Dec 2018 --> Jun 2019 Active, not recruiting --> Completed | N=270 --> 135 | Trial primary completion date: Apr 2017 --> May 2016
- Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - May 6, 2016
P1, N=9, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | N=270 --> 135 | Trial primary completion date: Apr 2017 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016
- floxuridine / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Surgery, Metastases: Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery (clinicaltrials.gov) - May 6, 2016
P1/2, N=28, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Oct 2016 Trial primary completion date: Apr 2016 --> Sep 2017
- Biomarker, Trial completion: Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients (clinicaltrials.gov) - May 6, 2016
P=N/A, N=200, Completed, Sponsor: St. Martin De Porress Hospital
Trial primary completion date: Apr 2016 --> Sep 2017 Recruiting --> Completed
- Trial primary completion date: Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection (clinicaltrials.gov) - May 6, 2016
P3, N=270, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Trial primary completion date: Apr 2016 --> Apr 2017
- Pegasys (pegylated interferon ? -2a) / Roche
Trial termination: An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure (clinicaltrials.gov) - May 5, 2016
P=N/A, N=282, Terminated, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2016 --> Apr 2017 Active, not recruiting --> Terminated
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - May 5, 2016
P2, N=106, Completed, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- | Victoza (liraglutide) / Novo Nordisk
Trial completion: MAGNA VICTORIA: Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients (clinicaltrials.gov) - May 5, 2016
P4, N=50, Completed, Sponsor: Leiden University Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- thalidomide / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Metastases: Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - May 4, 2016
P1/2, N=3, Terminated, Sponsor: National Health Research Institutes, Taiwan
Active, not recruiting --> Completed Trial primary completion date: Nov 2011 --> Jan 2010
- sorafenib / Generic mfg.
Enrollment change, Trial termination, Metastases: Sorafenib VS TACE in HCC Patients With Portal Vein Invasion (clinicaltrials.gov) - May 3, 2016
P2, N=2, Terminated, Sponsor: Seoul National University Hospital
Trial primary completion date: Nov 2011 --> Jan 2010 N=40 --> 2 | Recruiting --> Terminated; Difficulty of participant enrollment.
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial withdrawal, Metastases: Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=0, Withdrawn, Sponsor: Seoul National University Hospital
N=40 --> 2 | Recruiting --> Terminated; Difficulty of participant enrollment. N=40 --> 0 | Recruiting --> Withdrawn